GEN Exclusives

More »

GEN News Highlights

More »
Oct 11, 2006

Stem Cell Purification System Under Development

  • Aldagen and Innovative Micro Technology (IMT) formed an alliance to co-develop and commercialize a version of IMT’s Rare Cell Purification System customized specifically for clinical cell therapies. This system, called the Aldesorter™, will be used with Aldagen’s Aldesort® product to isolate unique stem cell populations to treat chronic heart failure, peripheral vascular disease, leukemias, genetic enzyme deficiencies, and other diseases.

    Aldagen’s Aldesort product is a set of reagents that can be used with currently available cell-sorting systems to isolate a highly potent population of stem and progenitor cells from human bone marrow, peripheral blood, and cord blood. Aldesort product’s chemistry allows the isolation of stem and progenitor cells, based on the elevated expression of an intracellular enzyme, aldehyde dehydrogenase.

    The first Aldesorter is scheduled for completion in early 2007, with clinical trials planned to begin in late 2007.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »